Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REGENERON PHARMACEUTICALS, INC. Director's Dealing 2021

Aug 16, 2021

29977_dirs_2021-08-16_d028c72c-2dec-4379-bafd-075788f39c14.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-08-13

Reporting Person: COLES N ANTHONY (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-08-13 Common Stock M 2000 $345.47 Acquired 2902 Direct
2021-08-13 Common Stock S 2000 $625.0 Disposed 902 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-08-13 Non-Qualified Stock Option (right to buy) $345.47 M 2000 Disposed 2027-01-27 Common Stock (2000) Direct

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.